Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 10 de 10
Filtrar
Más filtros











Base de datos
Intervalo de año de publicación
1.
Ugeskr Laeger ; 162(44): 5924-8, 2000 Oct 30.
Artículo en Danés | MEDLINE | ID: mdl-11094553

RESUMEN

INTRODUCTION: To compare an invasive strategy employing percutaneous transluminal coronary angioplasty (PTCA) or coronary artery by-pass grafting (CABG) with a medical strategy in patients who had received thrombolytic treatment for first acute myocardial infarction (AMI), and with signs of inducible ischaemia. METHODS: In a prospective study 1008 patients were randomized, 503 to invasive treatment, of whom 266 (52.9%) had PTCA, and 147 (29.2%) CABG, 505 to conservative treatment, of whom eight (1.6%) were revascularized within two months. RESULTS: After a median follow-up of 2.4 years the mortality in the invasive group was 3.6% vs. 4.4% (p = 0.45) in the conservative group, re-infarction incidence was 5.6% vs. 10.5% (p = 0.0038) and percentage of admissions with unstable angina was 17.9% vs. 29.5% (p < 0.00001). DISCUSSION: We conclude that post-infarct patients with inducible ischaemia should be referred to coronary angiography and revascularised accordingly.


Asunto(s)
Infarto del Miocardio/complicaciones , Isquemia Miocárdica/terapia , Terapia Trombolítica , Adulto , Anciano , Angina Inestable/diagnóstico , Angioplastia Coronaria con Balón , Puente de Arteria Coronaria , Dinamarca/epidemiología , Humanos , Incidencia , Persona de Mediana Edad , Infarto del Miocardio/tratamiento farmacológico , Infarto del Miocardio/mortalidad , Isquemia Miocárdica/tratamiento farmacológico , Isquemia Miocárdica/etiología , Isquemia Miocárdica/cirugía , Revascularización Miocárdica , Pronóstico , Estudios Prospectivos , Recurrencia , Resultado del Tratamiento
2.
Am J Cardiol ; 79(7): 961-3, 1997 Apr 01.
Artículo en Inglés | MEDLINE | ID: mdl-9104913

RESUMEN

We measured growth hormone-related substances in patients with angina pectoris precipitated by different underlying disorders. Although hyperinsulinemia was more pronounced in patients with angina pectoris secondary to atherosclerotic coronary disease than in patients with syndrome X and variant angina, we found no evidence that growth hormone-related substances including insulin-like growth factor-I are associated with coronary atherosclerosis.


Asunto(s)
Angina Pectoris Variable/complicaciones , Angina de Pecho/sangre , Angina de Pecho/etiología , Enfermedad de la Arteria Coronaria/complicaciones , Resistencia a la Insulina , Factor I del Crecimiento Similar a la Insulina/análisis , Insulina/sangre , Angina Microvascular/complicaciones , Angina Pectoris Variable/sangre , Enfermedad de la Arteria Coronaria/sangre , Femenino , Hormona de Crecimiento Humana/sangre , Humanos , Masculino , Angina Microvascular/sangre , Persona de Mediana Edad
3.
Ugeskr Laeger ; 158(46): 6605-8, 1996 Nov 11.
Artículo en Danés | MEDLINE | ID: mdl-8966826

RESUMEN

Angiopeptin, a somatostatin analogue, inhibits intimal hyperplasia after (percutaneous transluminal coronary angioplasty) (PTCA) in several animal models. This pilot study sought to determine the effect of subcutaneous infusion of angiopeptin on clinical events and restenosis in patients undergoing successful PTCA. One hundred and twelve patients were randomized to receive continuous subcutaneous angiopeptin (750 micrograms/day) or placebo infusion from the day before PTCA and for the following four days in a double-blind study. Eighty patients had a successful PTCA, and 75 of these patients with 94 lesions underwent angiography 6 +/- 2 months after PTCA. All 112 patients underwent clinical follow-up at 12 months. The 12-month event rate (death, myocardial infarction, coronary artery bypass grafting and re-PTCA) was reduced from 34% to 25% (p = 0.30) by angiopeptin by intention to treat analysis. Restenosis (> or = 50% diameter stenosis) was significantly reduced in lesions treated with angiopeptin (12% vs 40%; p = 0.003). Late lumen loss was also significantly reduced after angiopeptin treatment (0.12 +/- 0.46 mm vs 0.52 +/- 0.64 mm; p = 0.003). In conclusion, continuous subcutaneous angiopeptin infusion for five days tended to decrease clinical events and restenosis after PTCA.


Asunto(s)
Angioplastia Coronaria con Balón , Fármacos Cardiovasculares/administración & dosificación , Enfermedad Coronaria/prevención & control , Oligopéptidos/administración & dosificación , Somatostatina/análogos & derivados , Adolescente , Adulto , Anciano , Angioplastia Coronaria con Balón/efectos adversos , Enfermedad Coronaria/terapia , Método Doble Ciego , Femenino , Estudios de Seguimiento , Humanos , Masculino , Persona de Mediana Edad , Péptidos Cíclicos , Recurrencia , Somatostatina/administración & dosificación
4.
Am Heart J ; 130(1): 1-8, 1995 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-7611096

RESUMEN

Angiopeptin, a somatostatin analogue, inhibits intimal hyperplasia after percutaneous transluminal coronary artery balloon angioplasty (PTCA) in several animal models. This pilot study sought to determine the effect of subcutaneous infusion of angiopeptin on clinical events and restenosis in patients undergoing successful PTCA. One hundred twelve patients were randomized to receive continuous subcutaneous angiopeptin (750 micrograms/day) or placebo infusion from the day before PTCA and for the following 4 days in a double-blind study. An additional subcutaneous injection of 375 micrograms of angiopeptin or saline was given immediately before PTCA. Eighty patients had a successful PTCA, and 75 of these patients with 94 lesions underwent angiography 6 +/- 2 months after PTCA. All 112 patients underwent a 12-month clinical follow-up examination. Age, sex, smoking, diabetes, hypertension, hyperlipidemia, and morphologic features of stenosis were similar in both groups. The hierarchical 12-month event rate (death, myocardial infarction, coronary artery bypass grafting, and repeated PTCA) was reduced from 34% to 25% (p = 0.30) by angiopeptin by intention-to-treat analysis. Restenosis (> or = 50% diameter stenosis) was significantly reduced in lesions treated with angiopeptin (12% vs 40%; p = 0.003). Late lumen loss also was significantly reduced after angiopeptin treatment (0.12 +/- 0.46 mm vs 0.52 +/- 0.64 mm; p = 0.003). In conclusion, continuous subcutaneous angiopeptin infusion for 5 days tended to decrease clinical events and restenosis after PTCA.


Asunto(s)
Angioplastia Coronaria con Balón , Fármacos Cardiovasculares/uso terapéutico , Enfermedad Coronaria/prevención & control , Oligopéptidos/uso terapéutico , Somatostatina/análogos & derivados , Fármacos Cardiovasculares/efectos adversos , Angiografía Coronaria , Enfermedad Coronaria/diagnóstico por imagen , Enfermedad Coronaria/epidemiología , Método Doble Ciego , Femenino , Estudios de Seguimiento , Humanos , Incidencia , Masculino , Persona de Mediana Edad , Oligopéptidos/efectos adversos , Péptidos Cíclicos , Placebos , Recurrencia , Países Escandinavos y Nórdicos/epidemiología , Somatostatina/efectos adversos , Somatostatina/uso terapéutico , Estadística como Asunto , Factores de Tiempo , Resultado del Tratamiento
5.
Ugeskr Laeger ; 155(18): 1392-4, 1993 May 03.
Artículo en Danés | MEDLINE | ID: mdl-8497975

RESUMEN

This report describes the fate of two young men wrongly treated with thrombolysis for suspected myocardial infarction. Both had electrocardiographic changes upon admission. Correct diagnoses of aortic dissection and haemorrhagic pericarditis was obtained within a few hours, but, due to the prolonged disturbance of haemostasis, appropriate therapy could not be instituted, and outcome was fatal for both patients. These cases underline the importance of rigid ST criteria, and procedures for neutralization of thrombolysis are proposed.


Asunto(s)
Hemostasis/efectos de los fármacos , Infarto del Miocardio/diagnóstico , Estreptoquinasa/efectos adversos , Terapia Trombolítica/efectos adversos , Adulto , Disección Aórtica/diagnóstico , Aneurisma de la Aorta/diagnóstico , Errores Diagnósticos , Electrocardiografía , Humanos , Enfermedad Iatrogénica , Masculino , Persona de Mediana Edad , Infarto del Miocardio/tratamiento farmacológico , Pericarditis/diagnóstico , Estreptoquinasa/administración & dosificación
6.
Eur J Clin Invest ; 23(4): 234-9, 1993 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-8500515

RESUMEN

Eight patients with mild heart failure were treated in random order for 1 week with 2 mg bumethanide at 0800 and 1200 (treatment 1) h, 1 mg bumethanide at 0800, 1200, 1800, 2200 (treatment 2) and 5 mg bendroflumethiazide at 0800 and 1800 (treatment 3) h. The 'quality of life' did not differ significantly between the three treatment periods. At the presumed trough of the diuretic effect the circulating blood volume was largest during treatment 1; it was 6.3% smaller during treatment 2 (P < 0.02) and 6.7% lower during treatment 3 (P < 0.05). In comparison with treatment 1, the maximal increase in rate-pressure product during physical exercise was 24.6% higher in treatment 3. Compared with treatment 1 the area under the curve (AUC) for plasma lactate during physical exercise was 14% lower during treatment 2 (P < 0.05) and 18% lower during treatment 3 (P < 0.01). These findings suggest that the type of program for diuretic therapy influences the magnitude of inevitable diurnal fluctuations in body fluids, the ability of the heart to work and the ability of the body to adjust to the oxygen demand.


Asunto(s)
Diuréticos/uso terapéutico , Insuficiencia Cardíaca/tratamiento farmacológico , Anciano , Anciano de 80 o más Años , Bendroflumetiazida/administración & dosificación , Bendroflumetiazida/uso terapéutico , Volumen Sanguíneo/efectos de los fármacos , Bumetanida/administración & dosificación , Bumetanida/uso terapéutico , Ritmo Circadiano , Diuréticos/administración & dosificación , Esquema de Medicación , Ejercicio Físico/fisiología , Femenino , Insuficiencia Cardíaca/sangre , Insuficiencia Cardíaca/fisiopatología , Humanos , Lactatos/sangre , Ácido Láctico , Masculino , Persona de Mediana Edad
8.
Eur Heart J ; 13(6): 840-3, 1992 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-1623876

RESUMEN

This report describes the fate of two young men wrongly treated with thrombolysis for suspected myocardial infarction. Both had electrocardiographic changes upon admission. Correct diagnosis of aortic dissection and haemorrhagic pericarditis was obtained within a few hours, but due to the prolonged disturbance of haemostasis, appropriate therapy could not be instituted, and outcome was fatal for both patients. These cases underline the importance of rigid ST criteria, and procedures for neutralization of thrombolysis are proposed.


Asunto(s)
Infarto del Miocardio/diagnóstico , Estreptoquinasa/efectos adversos , Terapia Trombolítica/efectos adversos , Adulto , Disección Aórtica/diagnóstico , Errores Diagnósticos , Electrocardiografía , Femenino , Humanos , Masculino , Persona de Mediana Edad , Pericarditis/diagnóstico
9.
Int J Cardiol ; 35(2): 259-61, 1992 May.
Artículo en Inglés | MEDLINE | ID: mdl-1572746

RESUMEN

A patient with a giant aneurysm in the right coronary artery combined with dilated and tortuous left descending and circumflex arteries is described. The clinical features and implications are discussed.


Asunto(s)
Aneurisma Coronario/etiología , Síndrome de Ehlers-Danlos/complicaciones , Adulto , Aneurisma Coronario/diagnóstico por imagen , Aneurisma Coronario/cirugía , Angiografía Coronaria , Vasos Coronarios/cirugía , Síndrome de Ehlers-Danlos/cirugía , Femenino , Humanos
10.
Int J Cardiol ; 35(1): 127-9, 1992 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-1563872

RESUMEN

A patient with emboli in the cerebrum and in the iliac bifurcation complicating left atrial myxoma is described. The pathological features and clinical implications are discussed.


Asunto(s)
Embolia/etiología , Neoplasias Cardíacas/complicaciones , Embolia y Trombosis Intracraneal/etiología , Mixoma/complicaciones , Adulto , Aorta Abdominal , Femenino , Atrios Cardíacos , Humanos , Arteria Ilíaca
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA